|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||492.30 - 501.70|
|52 Week Range||312.00 - 512.70|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||31.85|
|Forward Dividend & Yield||5.75 (1.16%)|
|Ex-Dividend Date||Feb 17, 2020|
|1y Target Est||567.59|
Indian drugmaker Sun Pharmaceutical Industries Ltd said on Friday it was testing a plant-derived drug, AQCH, for the potential treatment of COVID-19 as part of a mid-stage trial, with results expected by October. AQCH is derived from tropical, climbing shrub cocculus hirsutus, which is used in Asia for its apparent medicinal properties. The company said the trial will be conducted across 12 centers in India in 210 patients and a human safety study of the drug has been completed.
Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in COVID-19 patients. The company joins other Indian drugmakers Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd that are conducting trials in India for potential drugs for COVID-19, which currently has no approved treatment or vaccine. Sun Pharma said http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200529:nBSE5stp4F the pancreatitis drug, nafamostat mesilate, has been "identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany".
Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment